As gene therapy programs move toward commercialization, fragmented data and complex CMC processes can create significant barriers to speed and scalability..png?width=141&height=199&name=Pdf%20thumbnail%20%20From%20Platform%20Promise%20To%20Commercial%20Reality%20Accelerating%20Gene%20Therapy%20Commercialization%20Through%20Structure%20(1).png)
In this article published in Cell & Gene, Viralgen explores how combining a standardized rAAV manufacturing platform with structured digital CMC data can help accelerate technology transfer, streamline onboarding, and reduce manufacturing inefficiencies — highlighting a recent sponsor onboarding that reduced an overall timeline of up to a year to just three months.
Download the full article to learn how structured data can help turn platform capabilities into measurable commercial impact.
